Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 18:59:55 Source:entertainmentViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:The unstoppable duo of Emma Stone and Yorgos Lanthimos
Next:Children are evacuated from school 'during an exam' after threat made via email
You may also like
- 'The Apprentice,' about a young Donald Trump, premieres in Cannes
- Knife attack at China school injures dozens
- Changes to road user charges will see EV owners paying more, climate expert says
- Ukraine lowers conscription age after drop in volunteers to fight Russian invasion
- Analysis: Larson enters conversation with Verstappen as best drivers in the world
- Foodstuffs recalls pre
- Wellington youth public transport fares to rise after government cuts funding
- Greens in 'defensive mode' over Golriz Ghahraman allegations
- Burglar hurled stolen mobile phones at police from the top of 60ft high roof during nine